The Economics of Reducing Antibiotic Use to Reduce Antimicrobial Resistance
Human consumption of antibiotics is only beneficial to societal welfare when the correct antibiotics are used and they are given at the right dose for the optimal length of time and only to those who need them. There are many cases in which these circumstances do not occur, thereby increasing the risk of adverse outcomes—one of the most important of which is antimicrobial resistance (AMR).
Given the strong association between antibiotic use (and overuse) and the development of antimicrobial resistance, the antibiotic market cannot be considered in the same light as other pharmaceutical products, such as medication to treat diabetes or cardiovascular disease, where overconsumption by one person would not have an adverse effect on another. This article discusses ways in which the market for antibiotics could internalize the negative externalities causes by excessive use of antibiotics to prevent the development of antimicrobial resistance.
Read the full article in AMR Control.
See also: ASSIST is pleased to have contributed these other articles to this edition of AMR Control:
- Using quality improvement to address hospital-acquired infections and antimicrobial resistance
- Improving rational antibiotic treatment of common childhood conditions in Uganda
- Embedding quality improvement through a learning collaborative to reduce and sustain hospital-acquired infections in the West Bank